Literature DB >> 17717200

Dendritic cells accumulate in human fibrotic interstitial lung disease.

Joëlle Marchal-Sommé1, Yurdagul Uzunhan, Sylvain Marchand-Adam, Marianne Kambouchner, Dominique Valeyre, Bruno Crestani, Paul Soler.   

Abstract

RATIONALE: There is growing evidence that resident cells, such as fibroblasts and epithelial cells, can drive the persistent accumulation of dendritic cells (DCs) in chronically inflamed tissue, leading to the organization and the maintenance of ectopic lymphoid aggregates. This phenomenon, occurring through a chemokine-mediated retention mechanism, has been documented in various disorders, but not in fibrotic interstitial lung disorders in which the presence of organized lymphoid follicles has been documented.
OBJECTIVES: To characterize the distribution of DCs in fibrotic lung, and to analyze the expression of the main chemokines known to regulate DC recruitment.
METHODS: Lung resection tissue (lungs with idiopathic pulmonary fibrosis; n = 12; lungs with nonspecific interstitial pneumonia, n = 5; control lungs, n = 5) was snap-frozen for subsequent immunohistochemical techniques on serial sections and reverse transcriptase-polymerase chain reaction analysis.
MEASUREMENTS AND MAIN RESULTS: Results were similar in idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia lungs, which were heavily infiltrated by immature DCs in established fibrosis and in areas of epithelial hyperplasia. Altered epithelial cells and fibroblasts, particularly in fibroblastic foci, frankly expressed all chemokines (CCL19, CCL20, CCL22, and CXCL12) susceptible to favor the recruitment of immune cells. Lymphoid follicles were infiltrated by maturing DCs, which could originate from the pool of DCs accumulating in their vicinity.
CONCLUSIONS: These findings suggest that resident cells in pulmonary fibrosis can sustain chronic inflammation by driving the accumulation of DCs with the potential to mature locally within ectopic lymphoid follicles. Future strategies should consider DCs or chemokines as therapeutic targets in the treatment of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17717200     DOI: 10.1164/rccm.200609-1347OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 2.  Chronic beryllium disease: an updated model interaction between innate and acquired immunity.

Authors:  Richard T Sawyer; Lisa A Maier
Journal:  Biometals       Date:  2010-10-28       Impact factor: 2.949

Review 3.  Dendritic cells: novel players in fibrosis and scleroderma.

Authors:  Theresa T Lu
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

4.  Lung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis.

Authors:  Taku Nakashima; Tianju Liu; Hongfeng Yu; Lin Ding; Matthew Ullenbruch; Biao Hu; Zhe Wu; Hideyuki Oguro; Sem H Phan
Journal:  Am J Respir Crit Care Med       Date:  2013-10-15       Impact factor: 21.405

5.  Cytokine-like factor 1 gene expression is enriched in idiopathic pulmonary fibrosis and drives the accumulation of CD4+ T cells in murine lungs: evidence for an antifibrotic role in bleomycin injury.

Authors:  Daniel J Kass; Guoying Yu; Katrina S Loh; Asaf Savir; Alain Borczuk; Rehan Kahloon; Brenda Juan-Guardela; Giuseppe Deiuliis; John Tedrow; Jiin Choi; Thomas Richards; Naftali Kaminski; Steven M Greenberg
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

6.  FIZZ2/RELM-β induction and role in pulmonary fibrosis.

Authors:  Tianju Liu; Hyun Ah Baek; Hongfeng Yu; Ho Jin Lee; Byung-Hyun Park; Matthew Ullenbruch; Jianhua Liu; Taku Nakashima; Yoon Young Choi; Gary D Wu; Myoung Ja Chung; Sem H Phan
Journal:  J Immunol       Date:  2011-05-20       Impact factor: 5.422

7.  Transcriptomic evidence of immune activation in macroscopically normal-appearing and scarred lung tissues in idiopathic pulmonary fibrosis.

Authors:  Irina G Luzina; Mariah V Salcedo; Mónica L Rojas-Peña; Anne E Wyman; Jeffrey R Galvin; Ashutosh Sachdeva; Andrew Clerman; June Kim; Teri J Franks; Edward J Britt; Jeffrey D Hasday; Si M Pham; Allen P Burke; Nevins W Todd; Sergei P Atamas
Journal:  Cell Immunol       Date:  2018-01-03       Impact factor: 4.868

8.  CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.

Authors:  Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

Review 9.  Linking immune responses with fibrosis in allergic eye disease.

Authors:  Sarah B Dale; Daniel R Saban
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-10

10.  Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.

Authors:  Yurika Yogo; Seitaro Fujishima; Takashi Inoue; Fumitake Saito; Takayuki Shiomi; Kazuhiro Yamaguchi; Akitoshi Ishizaka
Journal:  Respir Res       Date:  2009-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.